Genus plc Stock
There is an upward development for Genus plc compared to yesterday, with an increase of €0.60 (2.360%).
Pros and Cons of Genus plc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | 2.360% | -8.633% | -5.926% | 9.483% | -13.605% | -12.050% | -57.311% |
| Ligand Pharmaceuticals | 2.970% | 0.990% | 4.082% | 126.667% | 22.892% | 193.525% | 120.112% |
| United Therapeutics | -0.420% | -2.300% | -5.168% | 66.056% | 10.367% | 132.544% | 225.241% |
| Ionis Pharmaceuticals Inc. | 0.990% | -2.531% | 0.248% | 110.475% | -4.797% | 65.897% | 127.977% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat